SAVE THE CDC PROSTATE CANCER PROGRAM
President Obama’s fiscal year 2016 budget eliminates all funding for the Centers for Disease Control prostate cancer program. Congress has the power to protect the CDC Prostate Cancer program. We ask for your advocacy to protect this life [...]
The Twists and Turns For Provenge
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in [...]
Early Evidence, The USPSTF Blows – Higher-Risk Prostate Cancers Increase From 2011 to 2013
Between 2011 and 2013, the proportion of men diagnosed with intermediate- or high-risk prostate cancer, increased by 3% per year. Thank you members of the United States Preventive Services Task Force for realy blowing it [...]
Prostvac In Combination With Yervoy Yields A Survival Advantage
There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac [...]
Is Cabazitaxel Before Docetaxel The Future Way To Go? *
Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. [...]
*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?
Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or [...]